Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

Table 1. Summary of evidence: results of anti-vascular endothelial growth factor treatment on central retinal vein occlusion macular edema. n = 2 in second-year BRVO n = 3.5 in second-year CRVO ...

Objective To understand the efficacy of aspirin use for preventing ischaemic stroke after central retinal artery occlusion ... acute coronary syndrome, retinal vein occlusion, new-onset glaucoma, ...

They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

Aims Previous studies have suggested an association between retinal artery occlusion (RAO) and ischaemic stroke (IS ... Blood samples were transferred to a dedicated central laboratory at the end of ...